ABCZY:OTC-Abcam plc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 23.08

Change

0.00 (0.00)%

Market Cap

USD 4.35B

Volume

0.22M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Abcam plc, a life sciences company, researches, develops, and distributes biological reagents and tools for research, drug discovery, and diagnostics in the United States, China, Japan, Europe, the Middle East, Africa, and rest of Asia Pacific. The company offers various research products, including primary and secondary antibodies; ELISA and matched antibody pairs; cell and tissue imaging tools; cellular and biochemical assays; proteins and peptides; proteomics tools; agonists, antagonists, activators, and inhibitors; lysates; and multiplex assays. Its research products are used in the areas of cancer, cardiovascular, cell biology, developmental biology, epigenetics, nuclear signaling, immunology, metabolism, microbiology, neuroscience, signal transduction, and stem cells. Further, the company offers diagnostic and therapeutic solutions. The company also sells its products online. Abcam plc was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Company Website : http://www.abcam.com

Address : Discovery Drive, Cambridge, United Kingdom, CB2 0AX

Employees : 1,600

Fiscal Year End : June

Currency: USD

Country : USA

Technical Indicators

Beta : 0.40

52 Week High : 24.69

52 Week Low : 14.50

200 Day Moving Average : 18.93

50 Day Moving Average : 22.34

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-15 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-0.53 (-0.74%)

 USD166.62B 24.86 2.73
CSLLY CSL Limited

+1.46 (+1.42%)

 USD93.46B 35.27 20.32
CMXHF CSL Limited

+3.00 (+1.46%)

 USD93.21B 35.07 20.32
GNMSF Genmab A/S

-0.58 (-0.16%)

 USD23.21B 30.57 3.21
SBHMY Sino Biopharmaceutical Limited

N/A

 USD19.30B 42.57 3.63
SBMFF Sino Biopharmaceutical Limited

N/A

 USD19.30B 43.48 3.63
UCBJY UCB SA

+0.72 (+1.50%)

 USD17.97B 21.25 14.81
UCBJF UCB SA

N/A

 USD17.78B 21.82 14.81
PPTDF PeptiDream Inc

N/A

 USD5.46B 141.21 0.75
GENSF Genus plc

N/A

 USD4.70B 68.51 46.07

ETFs Containing ABCZY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.10% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.10% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 64.04% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 64.04% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 169.31% N/A N/A N/A N/A
Dividend Return 5.22% N/A N/A N/A N/A
Total Return 174.53% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 19.40% 47% F 63% D
Dividend Return 0.76% 17% F 26% F
Total Return 20.16% 46% F 62% D-
Risk Return Profile  
Volatility (Standard Deviation) 25.15% 91% A- 69% D+
Risk Adjusted Return 80.13% 96% A 95% A
Market Capitalization 4.35B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 48.62 N/A N/A N/A N/A
Price/Book Ratio 5.13 N/A N/A N/A N/A
Price / Cash Flow Ratio 69.05 N/A N/A N/A N/A
EV/EBITDA 141.88 N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -0.37% N/A N/A N/A N/A
Return on Invested Capital 2.94% N/A N/A N/A N/A
Return on Assets 2.94% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.40 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.